Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's [Seeking Alpha]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Seeking Alpha
LX1001 targets APOE4 homozygous patients with Alzheimer's disease by delivering a functional APOE2 gene using the AAVrh10 vector. Its other product, LX2006, targets FA cardiomyopathy using the same vector. Lexeo ( NASDAQ: LXEO ) is a small company and recent IPO which according to Evaluate has the rare distinction of getting the first gene therapy targeting Alzheimer's into the clinic - meaning in human trials. This is not exactly true; there have been a few other gene therapies targeting Alzheimer's in the clinic. But that does not reduce its achievement much; Lexeo is still one of a very few select companies with gene therapy programs in the clinic. It is also the only small company in the list. A few other such gene therapy trials: An April 2023 phase 1 trial sponsored and undertaken by UCL and UCLH uses a “gene silencing” approach using BIIB080 (/IONIS-MAPTRx) to target the gene coding for the tau protein production process. This asset, or a version of it, is now in phase
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics Announces First Quarter 2024 Conference Call and WebcastBusiness Wire
- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Business Wire
- What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today [Yahoo! Finance]Yahoo! Finance
SGMO
Earnings
- 3/13/24 - Miss
SGMO
Sec Filings
- 4/30/24 - Form 8-K
- 4/19/24 - Form ARS
- 4/19/24 - Form DEF
- SGMO's page on the SEC website